Cangrelor free acid is primarily used in the medical field as an antiplatelet agent. It is administered intravenously to prevent blood clots in patients undergoing percutaneous coronary intervention (PCI), a procedure to open blocked coronary arteries. Its rapid onset and short duration of action make it particularly useful in acute settings where immediate platelet inhibition is required. Additionally, it is often used in patients who cannot take oral antiplatelet medications or when a quick reversal of platelet inhibition is necessary. The compound is also studied for its potential use in other cardiovascular conditions where platelet aggregation plays a critical role.